VibroSense Dynamics AB (publ) applied for patent on biomarker to predict the risk of nerve damage caused by chemotherapy. The result from a clinical pilot study, in collaboration with the clinic of Oncology at the university hospitals in Lund and Malmö as well as the hospital in Kristianstad, shows that VibroSense Meter and its technology can be used to predict the risk of getting permanent nerve damage caused by treatment of cancer with chemotherapy. The discovery is an important step to pave the way for a new biomarker that can support physicians within cancer treatment with chemotherapy. The patent application is based on a study conducted during 2018-2020, on patients with colorectal cancer treated with oxaliplatin-based drugs. The patients' sensitivity was examined with VibroSense Meter on hands and feet, before the first treatment and then during the ongoing treatment for 3-6 months. A follow-up examination with VibroSense Meter was performed 6 months after the last chemotherapy treatment. The results strongly indicate that it is possible to identify patients at high risk of acquiring permanent nerve damage 6 months after the final treatment, by measuring the patients' sensitivity with the VibroSense Meter before the first chemotherapy treatment.